Drug
Encorafenib
Encorafenib: highest development phase Phase 3, developed by Pfizer, Pierre Fabre. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Pfizer, Pierre Fabre
Trials
| Drug | Phase | Indication |
|---|---|---|
| Encorafenib NCT04607421 | Phase 3 | Neoplasms |
| Encorafenib NCT05004350 | Phase 2 | BRAF V600E |
| encorafenib NCT03693170 | Phase 2 | BRAF V600E-mutant Metastatic Colorectal Cancer |
| Encorafenib NCT05195632 | Phase 2 | Non-Small Cell Lung Cancer |
Latest
No recent events.
Follow Encorafenib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.